GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » EKIMAS Corp (OTCPK:ASNB) » Definitions » Sloan Ratio %

EKIMAS (EKIMAS) Sloan Ratio % : 0.00% (As of Dec. 2022)


View and export this data going back to 1996. Start your Free Trial

What is EKIMAS Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

EKIMAS's Sloan Ratio for the quarter that ended in Dec. 2022 was 0.00%.

As of Dec. 2022, EKIMAS has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


EKIMAS Sloan Ratio % Historical Data

The historical data trend for EKIMAS's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EKIMAS Sloan Ratio % Chart

EKIMAS Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.27 15.06 2.41 - -

EKIMAS Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EKIMAS's Sloan Ratio %

For the Shell Companies subindustry, EKIMAS's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EKIMAS's Sloan Ratio % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, EKIMAS's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where EKIMAS's Sloan Ratio % falls into.



EKIMAS Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

EKIMAS's Sloan Ratio for the fiscal year that ended in Mar. 2022 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2022 )-Cash Flow from Operations (A: Mar. 2022 )
-Cash Flow from Investing (A: Mar. 2022 ))/Total Assets (A: Mar. 2022 )
=(-0.287--0.282
-0)/0.25
=-2.00%

EKIMAS's Sloan Ratio for the quarter that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2022 )
=(-5.986--0.216
-0)/0.006
=-96,166.67%

EKIMAS's Net Income for the trailing twelve months (TTM) ended in Dec. 2022 was -0.053 (Mar. 2022 ) + -5.035 (Jun. 2022 ) + -0.047 (Sep. 2022 ) + -0.851 (Dec. 2022 ) = $-5.99 Mil.
EKIMAS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2022 was -0.076 (Mar. 2022 ) + -0.06 (Jun. 2022 ) + -0.044 (Sep. 2022 ) + -0.036 (Dec. 2022 ) = $-0.22 Mil.
EKIMAS's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2022 was 0 (Mar. 2022 ) + 0 (Jun. 2022 ) + 0 (Sep. 2022 ) + 0 (Dec. 2022 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EKIMAS  (OTCPK:ASNB) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2022, EKIMAS has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


EKIMAS Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of EKIMAS's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


EKIMAS (EKIMAS) Business Description

Traded in Other Exchanges
N/A
Address
3651 Lindell Road, Suite D565, Las Vegas, NV, USA, 89103
EKIMAS Corp is a shell company.
Executives
Partners Aps Gk 10 percent owner MESTERLODDEN 3B, GENTOFTE G7 2820
Henrik Oerbekker 10 percent owner 94, RUE DES AUBEPINES, L-1145, LUXEMBOURG N4 2449
Henrik Rouf 10 percent owner 468 N. CAMDEN DR., SUITE 350, BEVERLY HILLS CA 90210
Khristine L Carroll officer: EVP Commercial Operations 229 ANDOVER STREET, WILMINGTON MA 01887
Michael F Adams director, officer: Chief Executive Officer 78 E OLYMPIA AVE, C/O CARDIO TECH INTERNATIONAL INC, WOBURN MA 01810-2057
David Crispino Volpe officer: Chief Financial Officer 235 STONEBRIDGE DRIVE, NASHUA NH 03063
Michael L Barretti director 78 E OLYMPIA AVE, C/O CARDIO TECH INTERNATIONAL INC, WOBURN MA 01810-2057
Oneill William J Jr director 4000 HOLLYWOOD BLVD STE 650N, HOLLYWOOD FL 33021
Mark R Tauscher director
Eric G Walters officer: Vice President and CFO C/O MFIC CORP, 30 OSSIPEE RD., NEWTON MA 02464
Andrew Martin Reed officer: VP of Science and Technology 12106 WEST 75TH LANE, ARVADA CO 80005
Philip Alan Beck other: General manager 1230 CREEKSIDE CROSSING, STILLWATER MN 55082
Jeremiah E Dorsey director P.O. BOX 910, QUECHEE VT 05059
Leslie M Taeger officer: CFO
Douglas E Whittaker officer: President Gish Biomedical